You are here

Vascepa

Are Amarin's Blockbuster Dreams Over?

Are Amarin's Blockbuster Dreams Over?

Motley Fool

Flag link:

Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

Fierce Pharma

Flag link:

Amarin aims for Vascepa boom with doubled sales force nearly in place

Amarin aims for Vascepa boom with doubled sales force nearly in place

Fierce Pharma

Flag link:

With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds

With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds

Fierce Pharma

Flag link:

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU

Fierce Pharma

Flag link:

AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up

AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up

Fierce Pharma

clinical trials

Flag link:

Vascepa sparkle set to light up Amarin's fourth quarter revenue

Vascepa sparkle set to light up Amarin's fourth quarter revenue

Endpoints

Flag link:

Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Yahoo/Marketwatch

Flag link:

Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion

Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion

Fierce Pharma

Flag link:

2 Top Biotech Buyout Candidates

2 Top Biotech Buyout Candidates

Motley Fool

Aurinia Pharmaceuticals

Flag link:

3 Biotechs Facing FDA Approvals by Year's End

3 Biotechs Facing FDA Approvals by Year's End

Motley Fool

Intra-Cellular Therapies

Flag link:

4 FDA Dates Biotech Investors Should Circle in December

4 FDA Dates Biotech Investors Should Circle in December

Motley Fool

anti-inflammatories

Bausch Health Companies

Intra-Cellular Therapies

Flag link:

Go or no go? Vascepa’s finale and Allergan's pain relief

Go or no go? Vascepa’s finale and Allergan's pain relief

EP Vantage

Flag link:

Before 2019 closes, the FDA has 3 key approval decisions to make

Before 2019 closes, the FDA has 3 key approval decisions to make

Biopharma Dive

Intra-Cellular Therapeutics

bipolar disorder

Flag link:

Does Amarin Have a Dark Horse Suitor?

Does Amarin Have a Dark Horse Suitor?

Motley Fool

Gilead Sciences

Flag link:

Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.

Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.

Motley Fool

Flag link:

Acasti plays catch-up to Amarin’s Vascepa

Acasti plays catch-up to Amarin’s Vascepa

EP Vantage

Flag link:

AHA: Amarin's Vascepa halts progression of arterial plaque in key study

AHA: Amarin's Vascepa halts progression of arterial plaque in key study

Fierce Pharma

Flag link:

What's next for Amarin? CEO John Thero talks Vascepa's label, pricing and future partnerships

What's next for Amarin? CEO John Thero talks Vascepa's label, pricing and future partnerships

Biopharma Dive

Flag link:

What's Next for Amarin's Stock?

What's Next for Amarin's Stock?

Motley Fool

advisory panels

Flag link:

Pages